These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 32346534)

  • 1. Local Dose Effects for Late Gastrointestinal Toxicity After Hypofractionated and Conventionally Fractionated Modern Radiotherapy for Prostate Cancer in the HYPRO Trial.
    Heemsbergen WD; Incrocci L; Pos FJ; Heijmen BJM; Witte MG
    Front Oncol; 2020; 10():469. PubMed ID: 32346534
    [No Abstract]   [Full Text] [Related]  

  • 2. Local Protocol Variations for Image Guided Radiation Therapy in the Multicenter Dutch Hypofractionation (HYPRO) Trial: Impact of Rectal Balloon and MRI Delineation on Anorectal Dose and Gastrointestinal Toxicity Levels.
    Wortel RC; Heemsbergen WD; Smeenk RJ; Witte MG; Krol SDG; Pos FJ; Incrocci L
    Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1243-1252. PubMed ID: 28943074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
    Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
    Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
    Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
    Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
    Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
    Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns in ano-rectal dose maps and the risk of late toxicity after prostate IMRT.
    Onjukka E; Fiorino C; Cicchetti A; Palorini F; Improta I; Gagliardi G; Cozzarini C; Degli Esposti C; Gabriele P; Valdagni R; Rancati T
    Acta Oncol; 2019 Dec; 58(12):1757-1764. PubMed ID: 31298076
    [No Abstract]   [Full Text] [Related]  

  • 7. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial.
    Yeoh EE; Fraser RJ; McGowan RE; Botten RJ; Di Matteo AC; Roos DE; Penniment MG; Borg MF
    Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):943-55. PubMed ID: 12605972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning.
    Sharfo AWM; Dirkx MLP; Bijman RG; Schillemans W; Breedveld S; Aluwini S; Pos F; Incrocci L; Heijmen BJM
    Radiother Oncol; 2018 Aug; 128(2):349-356. PubMed ID: 29885745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-surface maps identifying local dose-effects for acute gastrointestinal toxicity after radiotherapy for prostate cancer.
    Wortel RC; Witte MG; van der Heide UA; Pos FJ; Lebesque JV; van Herk M; Incrocci L; Heemsbergen WD
    Radiother Oncol; 2015 Dec; 117(3):515-20. PubMed ID: 26522060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-Reported Outcomes in the Acute Phase of the Randomized Hypofractionated Irradiation for Prostate Cancer (HYPRO) Trial.
    Sinzabakira F; Heemsbergen WD; Pos FJ; Incrocci L
    Int J Radiat Oncol Biol Phys; 2022 Mar; 112(4):870-879. PubMed ID: 34740766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-related risk factors for late rectal bleeding after hypofractionated radiotherapy for localized prostate cancer: a single-center retrospective study.
    Kim TG; Park B; Song YG; Lee HW; Oh TH; Ryu DS; Jeong SC; Cho D; Oh J; Kim KM; Lee JW; Lee HS; Kong SM; Kim JY; Kim H
    Radiat Oncol; 2022 Feb; 17(1):30. PubMed ID: 35139869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415.
    Thor M; Deasy JO; Paulus R; Robert Lee W; Amin MB; Bruner DW; Low DA; Shah AB; Malone SC; Michalski JM; Dayes IS; Seaward SA; Gore EM; Albert M; Pisansky TM; Faria SL; Chen Y; Koontz BF; Swanson GP; Pugh SL; Sandler HM
    Radiother Oncol; 2019 Jun; 135():19-24. PubMed ID: 31015166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients.
    Cozzarini C; Fiorino C; Deantoni C; Briganti A; Fodor A; La Macchia M; Noris Chiorda B; Rancoita PM; Suardi N; Zerbetto F; Calandrino R; Montorsi F; Di Muzio N
    Eur Urol; 2014 Dec; 66(6):1024-30. PubMed ID: 24985964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer: Results From a Randomized Trial.
    Hoffman KE; Skinner H; Pugh TJ; Voong KR; Levy LB; Choi S; Frank SJ; Lee AK; Mahmood U; McGuire SE; Schlembach PJ; Du W; Johnson J; Kudchadker RJ; Kuban DA
    Am J Clin Oncol; 2018 Jun; 41(6):558-567. PubMed ID: 27635624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial.
    de Vries KC; Wortel RC; Oomen-de Hoop E; Heemsbergen WD; Pos FJ; Incrocci L
    Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):108-115. PubMed ID: 31593756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
    Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
    Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose/volume relationship of late rectal bleeding after external beam radiotherapy for localized prostate cancer: absolute or relative rectal volume?
    Kupelian PA; Reddy CA; Carlson TP; Willoughby TR
    Cancer J; 2002; 8(1):62-6. PubMed ID: 11895204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
    Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute and Late Rectal Toxicity Following Hypofractionated Radiotherapy in Patients With Prostate Cancer: Results of a Prospective Study.
    Kounadis G; Syrigos N; Kougioumtzopoulou A; Bamias G; Kotteas I; Papatheodoridis G; Grapsa D
    In Vivo; 2022; 36(4):1875-1880. PubMed ID: 35738620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.